English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance The use of BRAF V600E-selective inhibitor dabrafenib and MEK inhibitor trametinib is a standard first-line treatment for human cancers harboringBRAF V600E. However, drug resistance/tumor recurrence is common with this treatment and the outcomes are unpredictable. We demonstrate here that dabrafenib and trametinib robustly induce cell apoptosis and hence abolishment of growth/regrowth of cancers harboring bothBRAF V600E andTERT promoter mutations with little effect in cells/tumors harboring onlyBRAF V600E. Thus,TERT promoter mutation, by governing the apoptotic and hence therapeutic sensitivities of BRAF-mutant cancer cells to BRAF/MEK inhibitors, may potentially be useful in helping patient selection for the inhibitor treatment and predicting therapeutic outcomes.

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF -mutant cancers to BRAF and MEK inhibitors: Achilles Heel